Dinaqor (Group)

https://www.dinaqor.com

LinkedIn: https://www.linkedin.com/company/dinaqor

DiNAQOR’s mission is to develop gene therapy solutions that transform the lives of patients with heart disease. Our novel and innovative gene therapy platform is focused on advancing treatments for patients affected by genetic cardiomyopathies, a disease of the heart muscle that can lead to heart failure. We were founded in April 2019 by a team of leading pharmaceutical and biotechnology executives and academics with deep cardiology and gene therapy expertise. We have established strategic partnerships with leading institutions and companies including Lonza and University Medical Center Hamburg-Eppendorf to advance our cardiac gene therapy platform and pipeline. Our company is headquartered in Pfäffikon, Switzerland, with additional presence in London, England and Boston, Massachusetts. *

	Start	2019-04-01 established
	Today	Dinaqor AG
	Industry	gene therapy
	Industry 2	cardiology
	Person	Holzmeister, Johannes (Dinaqor 202009 CEO + Co-Founder + Cardiorentis AG 201409 CEO + CMO)

	Region	Pfäffikon SZ
	Country	Switzerland
	Street	77 Churerstr.
	City	8808 Pfäffikon SZ
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		�About Section� taken from web site of organisation on 17.09.

		Record changed: 2023-07-10